Joy is a science.
Help us advance it.

First of their kind, and FDA approved, ZyMōt™ ICSI and ZyMōt Multi Sperm Separation Devices deliver the best
performing sperm for use in ICSI, IUI and IVF procedures.

WHAT IS ZyMōt™?

  • Overview
  • Multi (850μL)
  • Multi (3mL)
  • ICSI
  • ZyMōt™ ICSI and ZyMōt Multi Sperm Separation Devices simulate the cervical and uterine pathways that sperm must navigate to naturally fertilize an egg. By mimicking a process that has been preserved in nature for millions of years, ZyMōt devices make it possible to separate the healthiest, best-performing sperm for use in ART procedures, without the use of sperm-damaging chemicals or centrifugation.

  • The ZyMōt Multi (850μL) has an inlet port that communicates with the lower sample chamber. The sample chamber is separated from the upper collection chamber by a microporous filter. Untreated semen are added through the inlet port. After a period of time, the separated sperm are collected from the upper chamber through the outlet port.

    See how to use this device.

  • The ZyMōt Multi (3mL) has an inlet port that communicates with the lower sample chamber. The sample chamber is separated from the upper collection chamber by a microporous filter. Untreated semen are added through the inlet port. After a period of time, the separated sperm are collected from the upper chamber through the outlet port.

    See how to use this device.

  • The ZyMōt ICSI has 5 micro channels; each accommodating 2μL of semen. More than one micro channel is available to accommodate multiple separations. Each channel has an inlet port for applying the semen sample and an outlet port for collecting the motile sperm. The ports are connected by a fluid-filled micro channel in which the separating occurs. Untreated semen is added through the inlet port. After a period of time, the separated sperm are collected from the outlet port.

    See how to use this device.

The Case for a Better Sperm Selection Process

According to the World Health Organization, approximately 40–50%* of all infertility cases are due to “male factor” infertility—most often related to low concentration (oligospermia), poor motility (asthenospermia), and abnormal morphology (teratospermia). Since healthy sperm is critical to the success of ART procedures, why aren’t we doing more to protect them?

*ASRM. Quick Facts About Infertility. Available from:
https://www.reproductivefacts.org/faqs/quick-facts-about-infertility/. June 12, 2018.

Common sperm separation procedures, such as the density gradient method, can require multiple rounds of centrifugation. This practice is known to create sperm-damaging reactive oxygen species and DNA fragmentation, which can affect the outcomes of ART procedures. A novel approach to selecting the healthiest sperm is long overdue.

ZyMōt™ ICSI and ZyMōt Multi are innovative devices that efficiently isolate the healthiest, highest-motility sperm for use in ICSI, IUI and IVF procedures.

  • No sample prep
  • No centrifugation
  • No extensive training
  • No expensive equipment
  • Low ROS and DNA fragmentation

Life starts when we stop risking the health of the sperm.

Our microenvironment, created by the microchannels and micropores, creates barrier mechanisms for the separation and selection of sperm with higher motility, better morphology, and lower DNA fragmentation.

Density Gradient Centrifugation

Density gradient centrifugation (DGC) is a standard procedure for preparing sperm for ICSI, IUI and IVF. DGC uses a centrifuge and is known to cause ROS and DNA fragmentation.

VS

ZyMōt

ZyMōt facilitates fast and efficient separation without the use of a centrifuge, protecting and preserving the health of the sperm.

ZyMōt devices protect and preserve healthy sperm in order to deliver the best possible outcomes for ICSI, IUI and IVF procedures.

Key Metrics

DGC
00:25
00:30
2.02%
ZyMōt
00:05
00:00
0.39%
DGC
ZyMōt

SIMPLICITY – SAVES TIME & REDUCES ERROR

Collect sample.

Add sample to the inlet, and wash medium into the upper collection chamber.

Incubate at 37°C for 30 minutes.

Collect the champions.

ZyMōt devices require fewer steps to complete, are more efficient and scalable, and can reduce hands-on tech time by as much as 80%, when compared to density gradient centrifugation.

See how using ZyMōt devices compares to DGC in greater depth.

Download PDF

Clinical Performance

Higher Chromatin Integrity

ZyMōt products “yielded the highest progressively motile spermatozoa characterized by high DNA integrity.”1

 

– Dr. Gianpiero Palermo, Dr. Alessandra Parrella, et al (Weill Cornell Medicine)

  • 1ESHRE 2017: Selection of Spermatozoa with Higher Chromatin Integrity Through a Microfluidics Device

Comparison of MOTILITY between the raw specimen and the semen processed by density gradient centrifugation and by ZyMōt devices.

Comparison of DNA FRAGMENTATION between the raw specimen and the semen processed by density gradient centrifugation and by ZyMōt devices.

Lower DNA Fragmentation

“Microfluidic sorting of unprocessed semen allows for the selection of clinically usable sperm with lower DNA fragmentation than standard processing.” 2

 

– Dr. Mitch Rosen, Dr. Utkan Demirci, et al (Univ of Calif, San Francisco; Stanford Univ School of Medicine)

  • ASRM 2017: Microfluidic Sorting Selects Sperm for Clinical Use with Reduced DNA Damage Compared to Density Gradient Centrifugation in Split Semen Samples

 

 

Our Team

Our dynamic management team combines 200+ years of biomedical industry experience and is backed by scientific and clinical advisors who have dedicated their lives to expanding possibilities in their fields of expertise. Every one of the ZyMōt Fertility advisors shown below brings a great breadth of experience in transformative thinking and pioneering practices.

Utkan Demirci, Ph.D.

DxNow Co-founder, Director, Scientific Advisor

Dr. Demirci is a Professor with tenure at Stanford University. Before moving to Stanford, he was Associate Professor of Medicine and Health Sciences and Technology at the Harvard Medical School (HMS) and Massachusetts Institute of Technology (MIT). He received a bachelor’s degree (summa cum laude) from the University of Michigan, Ann Arbor; master’s degrees in Electrical Engineering in 2001 and in Management Science and Engineering in 2005, as well as a PhD in Electrical Engineering in 2005 all from Stanford University. Dr. Demirci is an academic entrepreneur with seminal contributions to the development of innovative microfluidic platform technologies in medicine for broad applications in fertility, cell sorting, and point-of-care diagnostics. He is recipient of the Academy for Radiology & Biomedical Imaging Research (ARBIR) Distinguished Investigator Award; MIT TR-35 Award; Harvard Medical School-Young Investigator Award; Stanford Basic Scientist of the Year Award; Brigham and Women’s Hospital-Bright Future Award; IEEE EMBS Early Career Award; IEEE EMBS Translational Science Award; NSF CAREER Award; Coulter Foundation Early Career Award; and Chinese International Young Scientist Award. He holds 25 issued or pending patents, provisionals, and disclosures that have been licensed to companies. He has published 146 articles, 24 book chapters/editorials, and 4 edited books, and serves as an editorial board member for various peer-reviewed journals. Dr. Demirci is also a fellow-elect of American Institute of Medical and Biological Engineering (AIMBE).

Barry Behr, Ph.D., H.C.L.D.

DxNow Clinical Advisory Board member

Dr. Behr is the Director of the IVF/ART Laboratory and Co-Director of the REI-IVF program, both at Stanford University, and is the Director of the Renew Biobank Institute for Stem Cell Biology and Regenerative Medicine. Dr. Behr is a nationally and internationally renowned clinical and scientific leader in the research and advances of human reproduction. As a world-renowned scientist and lecturer, he is highly sought after to chair scientific programs and conferences, is the first non-MD President of the Pacific Coast Reproductive Society and has been appointed as program chairman of several professional meetings. Dr. Behr has been widely recognized for his research and has published over 200 peer-reviewed publications and book chapters.

Gianpiero D. Palermo, M.D., Ph.D.

DxNow Clinical Advisory Board member

Dr. Palermo is the pioneer of intracytoplasmic sperm injection (ICSI), a ground-breaking technique that has transformed the treatment of male factor infertility and fertilization failure. Ever since its inception in 1992, ICSI has assisted thousands of men to achieve biologic paternity. Beginning 1993, Dr. Palermo has been the Director of Assisted Fertilization and Andrology at the Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, New York, one of the world’s largest ICSI programs. In his capacity as the Blavatnik Distinguished Professor of Reproductive Medicine, he leads a talented team of researchers comprising of andrologists and clinical fellows who investigate the molecular aspects of fertilization, genetic and epigenetic aspects of male infertility, follow-up of ICSI babies and the development and differentiation of embryonic stem cells. He has published over 76 book chapters, 327 abstracts, and 132 research papers, which have been featured in journals such as the New England Journal of Medicine, Lancet, JAMA, Human Reproduction, Fertility and Sterility, and PLOS One. He is the recipient of multiple awards, including the Jacob Heskel Gabbay Award in Biotechnology and Medicine awarded by the Rosenstiel Basic Medical Sciences Research Center and Brandeis University, the Barbara Eck Menning Founders Award, and the Francavilla Fontana Illustrious Citizen Award.

Mitchell Rosen, M.D.

DxNow Clinical Advisory Board member

Dr. Rosen serves on the faculty at UCSF and is the Director of the UCSF Reproductive Laboratories and Fertility Preservation Program, one of the largest programs in the USA. He received his medical training at St. Louis University and completed his residency in Obstetrics and Gynecology at the University of Texas Medical Branch. Dr. Rosen subsequently received his training in Reproductive Endocrinology and Infertility at UCSF. He is board certified in both Obstetrics and Gynecology and Reproductive Endocrinology and Infertility. In addition, to further understand the IVF process, he also trained as an embryologist and serves as the laboratory director at UCSF. Knowledge of both the clinical and laboratory aspects of assisted reproduction has allowed him to focus his clinical work and research endeavors on optimizing IVF outcomes, and preserving fertility. As a result of his work, he has published numerous manuscripts and chapters that have significantly contributed to the field.

Paul Turek, M.D.

DxNow Clinical Advisory Board member

Dr. Turek is a board-certified urologist and microsurgeon, specializing in male fertility. He has performed and published research in men’s reproductive health issues including genetic infertility, ejaculatory duct obstruction, immunologic infertility, quality of life issues with infertility, testis cancer and stem cell science, and has developed several techniques for evaluating and treating male infertility. While at UCSF, he was Director of the Male Reproductive Clinical Laboratory, Program Leader of PROGENI (The Program in the Genetics of Infertility), Director of the UCSF Men’s Reproductive Health Clinic and Research Program, and the director of a National Institutes of Health grant to train new faculty in men’s reproductive health. He has authored more than 175 publications on clinical and scientific issues in reproductive health. Through his published work, he is a proponent of the theory that male infertility is an early marker for other diseases that occur later in life. He became a full professor, with an endowed chair in teaching funded by the Academy at UCSF, a chair he later abandoned in favor of starting his own private clinic. He is now Director of The Turek Clinic, a medical center that specializes exclusively in men’s reproductive health care. The clinic is dedicated to treating the unique conditions that affect reproductive age men. He was President in 2011 of the American Society of Andrology.

Learn more about the future of fertility

By eliminating damaging chemicals and centrifugation, ZyMōt ICSI and ZyMōt Multi Sperm Separation Devices truly set themselves apart from other sperm separation methods. To receive more information or to speak with one of our specialists, please complete the form below.

Professionals Patients